Quantitative Concept
Gilead Sciences Exceeds Q2 Expectations, Boosts Optimism for Seladelpar Decision
Gilead Sciences, Q2 earnings, seladelpar, PBC, liver disease, financial performance, pharmaceuticals
Madrigal’s MASH Drug Rezdiffra Surpasses Q2 Sales Estimates
Madrigal Pharmaceuticals, Rezdiffra, MASH drug, Q2 earnings, sales estimates, FDA approval, commercial launch, NASH treatment
FDA Approves Servier’s Brain Cancer Drug, Triggering $1 Billion Payout for Agios
FDA approval, Servier, brain cancer drug, Voranigo, Agios Pharmaceuticals, IDH1 and IDH2 mutations, blood-brain barrier, cancer metabolism, royalty payments
Pharma Campaign Contributions, Vaccine Hiccups, and Lykos’ Moment of Truth
Pharma campaign contributions, vaccine hiccups, Lykos Therapeutics, MDMA-assisted treatment, FDA approvals, Q2 earnings, biopharma challenges
Bayer Accelerates Managerial Job Cuts in Ongoing Transformation Efforts
Bayer, managerial job cuts, CEO Bill Anderson, Dynamic Shared Ownership, restructuring, cost savings, pharmaceutical industry
Mallinckrodt Sells Immunotherapy Business to CVC Capital for $925 Million
Mallinckrodt, CVC Capital, immunotherapy, Therakos, $925 million deal
BioMarin Restricts Roctavian Sales to U.S., Germany, and Italy Amid Stagnant Sales
BioMarin, Roctavian, hemophilia A gene therapy, U.S., Germany, Italy, sales strategy, profitability, cost reduction
Symbiotic Capital Launches with $600M, Ties to Arie Belldegrun’s Bellco
Symbiotic Capital, Arie Belldegrun, Bellco, $600M, credit firm, biotech, private equity
Bayer Announces 3,200 Job Cuts, Highlights Progress in Pharmaceutical Pipeline
Bayer, job cuts, pharmaceutical pipeline, cost savings, organizational restructuring
23andMe Board Rejects CEO Anne Wojcicki’s Take-Private Plan, Requests Changes
23andMe, Anne Wojcicki, take-private plan, board rejection, financing, stock price, shareholders